Saturday, May 30, 2015

Hooves not nails



Dear  Rev  Humberto Chavez:


      As the number ofnassau OTB branches continues to shrink people are afraid and silent.  Some of your flock may bet at the Franklin square branch of Nassau OTB.  Please tell our governor and
Elected officials that Nassau OTB  may not close on roman. Catholic. Palm Sunday  and
Easter Sunday  in preference to Greek. Orthodox Easter Sunday and palm Sunday.
     Please make your views known.  






Photo

The Rev. Humberto Chavez, right, with the trainer and former jockey Andrew Lakeman, left, on Tuesday at Belmont Park in Elmont, N.Y. As a chaplain, Mr. Chavez covers Belmont, Aqueduct and Saratoga. CreditVictor J. Blue for The New York Times

ELMONT, N.Y. — In his years as a chaplain to grooms and hot walkers and exercise riders and the rest of the workers at three racetracks in New York State, the Rev. Humberto Chavez had made countless hospital visits and seen more than enough fractured skulls and shattered legs. Nothing, however, prepared him for the sight of a jockey named Andrew Lakeman in a Long Island medical center one night in May 2007.
Tendrils of tubing protruded from Mr. Lakeman’s head. His body was encased in a sort of inflatable cocoon, meant to keep him in an inducedcoma. Several hours earlier, a tangle of legs between two horses at Belmont Park had hurled Mr. Lakeman to the ground. Stomped by a trailing thoroughbred, he was paralyzed with a severed spine and left near death with a punctured lung.
Mr. Chavez had gone through so much with Mr. Lakeman already. A few years earlier, when the jockey had lost his racing license to drug and alcohol addiction, he sought the minister’s help in going into recovery and ultimately regaining his credentials. Now this: an inert body, barely alive, and a request from the hospital that the chaplain try to reach Mr. Lakeman’s family in England.



Photo

Patricia Perez with Saratoga Karaoke as she and other workers completed the morning barn work on Tuesday. The "backside" or "backstretch" of racetracks is often a place of physical danger and psychological struggle. CreditVictor J. Blue for The New York Times

After the jockey came out of his coma and began six months of arduous rehabilitation, it fell to Mr. Chavez to speak words that were both rigid and tender. “If you don’t turn the page and start a new chapter, it is not going to go well,” the chaplain recalled having said. “This can be a new beginning, a new path.”
As Mr. Chavez walked the grounds of Belmont a few days ago, doing the morning rounds of his de facto parish, he spotted a van pulling up to a barn. Out of the vehicle rolled Mr. Lakeman in his wheelchair, starting his own day’s work as a trainer, the new chapter of life that Mr. Chavez had urged upon him. The stall that Mr. Lakeman uses for an office features photographs of his winners — El Deal, Shes Loca, All Zipped Up — and a painting of Jesus.
Mr. Lakeman, 40, said of the chaplain: “He was easygoing, easy to talk to, more like a friend than a minister. He comforted me and he gave me strength.”
If the parable is one of religion’s primary teaching tools, then the relationship between the chaplain and the jockey offers a parable for the larger role that Mr. Chavez and clergy members like him play for the racing community nationwide. Mr. Chavez is one of 26 ministers affiliated with the Race Track Chaplaincy of America, which serves 30 tracks in 18 states. He covers Aqueduct, Belmont and Saratoga.
The chaplaincy was conceived in 1969 by an exercise rider in Florida and was incorporated in 1972. It came to New York in 1986. Then as now, the ministry meant to bring not only God’s word but also concrete forms of assistance to the people of the “backside” or “backstretch,” as the largely unseen community of racetrack workers is known.
For all the glamour and wealth associated with horse racing, the backside is often a place of physical danger and psychological struggle. “Every sin that you can imagine that’s out in the community is here,” Mr. Chavez, 38, said. “Addiction, loneliness, financial trouble. The language and culture are a big learning curve, because most of the people are immigrants. Life here is difficult, even if you’re from Kentucky.”
“I’ll get a tip about someone who’s not doing well. ‘Hey, he didn’t show up for work,’ ” he said. “A trainer might call me, and say, ‘We haven’t seen him for two days. Can you check?’ Or a family member from overseas tells me, ‘We haven’t heard from him in a month. He hasn’t been sending us money.’ ”
Summer is especially busy and demanding. The Belmont Stakes next Saturday will draw international attention and nearly 100,000 fans, and the Saratoga racing season starts July 24. Each track, as a result, will have about 1,000 workers living on the backside, with more in neighborhoods nearby.
What they need from Mr. Chavez varies widely, and the range could be seen as he walked the Belmont grounds early on Memorial Day. It was a racing day, and at 8:30 a.m. the horses were returned to barns to rest between sunrise workouts and the afternoon’s card. The air sounded of bird songs and clopping hooves and the accordion strains of a Mexican corrido playing from a radio.
At one barn, a foreman named Antonio Amezcua explained that one of his children had just turned 16 and could start working; Mr. Chavez promised to help fill out the application for a job as a parking-lot attendant. At another point, the minister hailed an exercise rider, Fernando Contreras, who has three children, to remind him about a backpack giveaway on June 21. In another barn, an assistant trainer asked Mr. Chavez to help her with the paperwork to extend her visa.
In more than a decade as a chaplain, Mr. Chavez has performed weddings in the grandstand, offered prayers to competing horses, distributed Thanksgiving turkeys, chaperoned children on outings to Six Flags Great Adventure and, of course, led innumerable worship services. In deference to the racing calendar, which bustles on the weekend, Monday night often substitutes for Sunday morning as church time.
While Mr. Chavez has never worked in the racing industry, he shares a fair amount of personal history with his flock. He was born in Mexico and came fatherless to Long Island at age 9. His mother supported the family by cleaning houses and selling Amway products, and Mr. Chavez went into the rugged existence of a construction laborer, ultimately becoming a carpenter and a general contractor.
The call to ministry first sounded after his mother recovered from thyroid cancer. That call became stronger when Mr. Chavez went on a mission trip to El Salvador, encountering poverty that made his own blue-collar existence seem unconscionably privileged.
After seminary study and ordination as a nondenominational Protestant, Mr. Chavez began volunteering at his brother-in-law’s church, which was right across the street from Belmont Park. He then started assisting the Belmont chaplain, the Rev. James Watson, and after he retired in 2003, Mr. Chavez took on the job with the Race Track Chaplaincy. (The New York State branch has an annual budget of $350,000, raised from personal and church donations as well as foundation grants.)
It is often said a successful jockey has “good hands” with a horse. Not coincidentally, a painting on the side of Mr. Chavez’s van shows two supernatural hands cupping a jockey on his mount. “On the backstretch,” the chaplain put it, “we are God’s hands.”



Friday, May 29, 2015

Ex to do yourself




Shoot Bcg. And observe the results
Bcg works for plaque psoriasis and multiple sclerosis et al

The us values life so much or so little that it made faustman establish the   Safety of Bcg in a phase 1 trial

The us and drug companies are severely broken


Morphine producing yeastcoming to a beer distributor near you.



If you have  MS. Read pubmed.org RISTORI +Bcg





Speeding up drug-approval process could have downside

Share This Page
Consumer advocates have expressed concern that the 21st Century Cures legislation, which would speed up the drug-approval process, could lower standards for approving new uses of existing drugs.
Consumer advocates have expressed concern that the 21st Century Cures legislation, which would speed up the drug-approval process, could lower standards for approving new uses of existing drugs. While supporters say the measure—approved recently by the House Energy and Commerce Committee—has been a long time coming, critics have taken issue with a part of the bill focused on drug development. They note that language in the bill would allow FDA to approve additional uses of drugs without having to rely on randomized, controlled trials. Instead, the bill lists "clinical experience," a combination of observational studies, patient registries, and therapeutic use. "Clinical experience is something that should be considered as additional information, but absolutely never take the place of scientific data," says Diana Zuckerman, heads of the nonprofit National Center for Health Research. "By urging FDA to get away from randomized clinical trials, drug makers may have more power to urge the FDA to consider data that is favorable to their product." The measure does not require FDA to consider such information when reviewing new uses for a drug, but Stanford University School of Medicine's Steve Goodman asserts that using the type of data suggested in the bill could make it hard for FDA to develop guidelines. "This doesn't have to mean the standard of evidence will be lowered, but it potentially opens the door to a weaker standard," he explains.
Trial record 1 of 2 for:    Faustman
Previous Study | Return to List | Next Study

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified May 2015 by Massachusetts General Hospital
Sponsor:
Information provided by (Responsible Party):
Denise Louise Faustman, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT02081326
First received: March 4, 2014
Last updated: May 21, 2015
Last verified: May 2015
  Purpose
The purpose of this study is to see if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect on Type 1 diabetes. Published Phase I data on repeat BCG vaccinations in long term diabetics showed specific death of some of the disease causing bad white blood cells and also showed a short and small pancreas effect of restored insulin secretion. In this Phase II study, the investigators will attempt to vaccinate more frequently to see if these desirable effects can be more sustained.
Eligible volunteers will either be vaccinated with BCG in a repeat fashion over a period of four years or receive a placebo treatment. The investigators hypothesize that each BCG vaccination will eliminate more and more of the disease causing white blood cells that could offer relief to the pancreas for increased survival and restoration of insulin secretion from the pancreas.

ConditionInterventionPhase
Diabetes Mellitus, Type One
Diabetes Mellitus, Type I
Autoimmune Diabetes
Biological: Bacillus Calmette-Guérin
Biological: Saline injection
Phase 2

Study Type:Interventional
Study Design:Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title:Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Improvement in HbA1c [ Time Frame: 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ] [ Designated as safety issue: No ]
    An improvement in the hemoglobin A1c (HbA1c) measurement compared to self

Secondary Outcome Measures:
  • Change in Immune Response [ Time Frame: 2 and 4 weeks and 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ] [ Designated as safety issue: No ]
    Beneficial immune changes of autoimmune reversal that may also lead to a change in insulin

Other Outcome Measures:
  • Stabilization in Urinary C-peptide [ Time Frame: 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ] [ Designated as safety issue: No ]
    Stabilization or improvement in urinary c-peptide of BCG treated group as compared to placebo group or self
  • Stabilization of Stimulated C-peptide [ Time Frame: 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ] [ Designated as safety issue: No ]
    Improvement or stabilization in stimulated C-peptide (self insulin) as measured by a mixed meal tolerance test (MMTT) when compared to self or placebo treated group

Estimated Enrollment:150
Study Start Date:July 2015
Estimated Study Completion Date:July 2023
Estimated Primary Completion Date:July 2020 (Final data collection date for primary outcome measure)
ArmsAssigned Interventions
Experimental: Bacillus Calmette-Guérin
2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
Biological: Bacillus Calmette-Guérin
2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
Placebo Comparator: Saline injection
2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
Biological: Saline injection
2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years

  Eligibility

Ages Eligible for Study:  18 Years to 65 Years
Genders Eligible for Study:  Both
Accepts Healthy Volunteers:  No
Criteria
Inclusion Criteria:
  • Type 1 diabetes treated continuously with insulin from time of diagnosis
  • Age 18-65
  • HIV antibody negative
  • Normal CBC
  • HCG negative (females)
  • Anti-GAD Positive (except for subjects with c-peptide <10pmol/L)
  • Fasting or stimulated c-peptide between 5-200 pmol/L
  • Participation in protocol #2001P001379, "Autoimmunity: In Vitro Pathogenesis and Early Detection"
Exclusion Criteria:
  • History of chronic infectious disease such as HIV or hepatitis
  • History of tuberculosis, TB risk factors, positive interferon-gamma release assay (IGRA, also known as the T-SPOT.TB test), or BCG vaccination
  • Current treatment with glucocorticoids (other than intermittent nasal or eye steroids), or disease or condition likely to require steroid therapy
  • Other conditions or treatments associated with increased risk of infections such as patients with a previous history of severe burns, or treatment with immunosuppressive medications of any type (e.g. imuran, methotrexate, cyclosporine, etanercept, infliximab) for any reason
  • Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs
  • Current treatment with antibiotics
  • History of keloid formation
  • Average HbA1c over the past 5 years (or since diagnosis if duration is less than 5 years) <6.5 or > 8.5%
  • History or evidence of chronic kidney disease (serum creatinine > 1.5mg/dL)
  • History of proliferative diabetic retinopathy that has not been treated with laser therapy
  • History of neuropathy, foot ulcers, amputations, or kidney disease
  • Pregnant or not using acceptable birth control
  • Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example HIV+ or taking immunosuppressive medications for any reason)